1. Home
  2. MCK vs REGN Comparison

MCK vs REGN Comparison

Compare MCK & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo McKesson Corporation

MCK

McKesson Corporation

HOLD

Current Price

$797.34

Market Cap

91.0B

Sector

Health Care

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$617.02

Market Cap

73.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCK
REGN
Founded
1833
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.0B
73.2B
IPO Year
1995
1995

Fundamental Metrics

Financial Performance
Metric
MCK
REGN
Price
$797.34
$617.02
Analyst Decision
Strong Buy
Buy
Analyst Count
14
25
Target Price
$952.92
$830.16
AVG Volume (30 Days)
935.8K
1.1M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
0.40%
0.55%
EPS Growth
49.22
8.19
EPS
38.38
6.75
Revenue
$112,084,000,000.00
$5,872,227,000.00
Revenue This Year
$14.94
$12.45
Revenue Next Year
$8.21
$10.13
P/E Ratio
$20.59
$89.08
Revenue Growth
3.11
20.82
52 Week Low
$637.00
$503.25
52 Week High
$999.00
$821.11

Technical Indicators

Market Signals
Indicator
MCK
REGN
Relative Strength Index (RSI) 59.21 39.68
Support Level $796.22 $610.60
Resistance Level $846.29 $618.01
Average True Range (ATR) 15.48 15.83
MACD 8.93 2.17
Stochastic Oscillator 96.25 45.16

Price Performance

Historical Comparison
MCK
REGN

About MCK McKesson Corporation

McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: